DaVita Inc. (NYSE:DVA) Shares Sold by Ensign Peak Advisors Inc

Ensign Peak Advisors Inc decreased its position in shares of DaVita Inc. (NYSE:DVA) by 22.0% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 22,172 shares of the company’s stock after selling 6,270 shares during the period. Ensign Peak Advisors Inc’s holdings in DaVita were worth $3,072,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in shares of DaVita by 2.4% in the fourth quarter. Vanguard Group Inc. now owns 6,320,740 shares of the company’s stock worth $662,161,000 after acquiring an additional 145,711 shares in the last quarter. Gates Capital Management Inc. boosted its stake in shares of DaVita by 3.1% during the 4th quarter. Gates Capital Management Inc. now owns 905,830 shares of the company’s stock valued at $94,895,000 after buying an additional 27,660 shares during the last quarter. 8 Knots Management LLC bought a new stake in shares of DaVita in the fourth quarter worth $89,504,000. Allianz Asset Management GmbH boosted its stake in DaVita by 63.9% during the 4th quarter. Allianz Asset Management GmbH now owns 548,642 shares of the company’s stock valued at $57,476,000 after acquiring an additional 213,992 shares during the last quarter. Finally, Doma Perpetual Capital Management LLC acquired a new position in DaVita during the 4th quarter worth $53,076,000. Institutional investors and hedge funds own 90.12% of the company’s stock.

Insiders Place Their Bets

In other news, insider Kathleen Alyce Waters sold 7,857 shares of the firm’s stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $146.21, for a total transaction of $1,148,771.97. Following the transaction, the insider now directly owns 83,011 shares of the company’s stock, valued at $12,137,038.31. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Javier Rodriguez sold 50,000 shares of DaVita stock in a transaction on Monday, September 16th. The stock was sold at an average price of $165.05, for a total transaction of $8,252,500.00. Following the transaction, the chief executive officer now directly owns 837,835 shares in the company, valued at approximately $138,284,666.75. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Kathleen Alyce Waters sold 7,857 shares of the company’s stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $146.21, for a total value of $1,148,771.97. Following the completion of the sale, the insider now owns 83,011 shares of the company’s stock, valued at approximately $12,137,038.31. The disclosure for this sale can be found here. In the last quarter, insiders sold 173,482 shares of company stock worth $27,387,069. 2.00% of the stock is owned by company insiders.

DaVita Stock Performance

Shares of DVA opened at $162.26 on Friday. The company has a debt-to-equity ratio of 9.94, a quick ratio of 1.12 and a current ratio of 1.16. DaVita Inc. has a 1 year low of $71.51 and a 1 year high of $166.04. The firm has a fifty day moving average of $149.64 and a 200-day moving average of $141.90. The company has a market cap of $13.61 billion, a price-to-earnings ratio of 18.44, a price-to-earnings-growth ratio of 0.93 and a beta of 0.87.

DaVita (NYSE:DVA) last posted its earnings results on Tuesday, August 6th. The company reported $2.59 EPS for the quarter, topping the consensus estimate of $2.47 by $0.12. DaVita had a net margin of 6.86% and a return on equity of 77.00%. The firm had revenue of $3.19 billion during the quarter, compared to analysts’ expectations of $3.15 billion. During the same quarter in the prior year, the firm earned $2.08 EPS. DaVita’s quarterly revenue was up 6.2% on a year-over-year basis. As a group, equities analysts anticipate that DaVita Inc. will post 9.99 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on DVA. Bank of America upped their target price on shares of DaVita from $139.00 to $145.00 and gave the company an “underperform” rating in a research note on Wednesday, August 7th. UBS Group boosted their price target on DaVita from $169.00 to $175.00 and gave the company a “buy” rating in a report on Thursday, August 8th. Truist Financial raised their price objective on DaVita from $150.00 to $165.00 and gave the stock a “hold” rating in a research note on Tuesday, August 20th. TD Cowen increased their target price on shares of DaVita from $139.00 to $150.00 and gave the stock a “hold” rating in a report on Wednesday, July 24th. Finally, StockNews.com lowered shares of DaVita from a “strong-buy” rating to a “buy” rating in a report on Saturday, June 8th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, DaVita has an average rating of “Hold” and a consensus target price of $157.00.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.